Aclaris Therapeutics, Inc. (ACRS)

Name: Aclaris Therapeutics, Inc. (ACRS) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001557746 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Aclaris Therapeutics, Inc. reported revenue of $7.83M. Revenue fell 58.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $8.22M.

Key ratios (year ended 2025-12-31)

73.3%

Gross margin (computed)

-975.9%

Operating margin

-829.6%

Net margin

-63.0%

Return on year-end equity

-58.2%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-08-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$8.22M	$7.83M	$18.72M	$31.25M	$29.75M	$6.76M	$6.48M	$4.23M	$6.15M	$1.68M	n/a
Cost of Revenue	$1.68M	$2.09M	$2.79M	$3.42M	$4.02M	$4.71M	$5.13M	$4.05M	$4.33M	$1.21M	n/a
Gross Profit (computed)	$6.54M	$5.74M	$15.93M	$27.83M	$25.73M	$2.05M	$1.35M	$172.0K	$1.82M	$476.0K	n/a
R&D Expense	$63.34M	$52.65M	$33.59M	$98.38M	$77.81M	$43.81M	$29.34M	$64.17M	$60.84M	$35.80M	$33.48M
Operating Income	-$86.31M	-$76.38M	-$141.93M	-$97.36M	-$89.85M	-$89.72M	-$50.91M	-$111.06M	-$84.78M	-$54.36M	-$48.57M
Depreciation & Amortization	$421.0K	$454.0K	$807.0K	$863.0K	$797.0K	$923.0K	$1.32M	$6.41M	$1.88M	$402.0K	$120.0K
EBITDA	-$85.89M	-$75.92M	-$141.12M	-$96.49M	-$89.06M	-$88.80M	-$49.59M	-$104.65M	-$82.90M	-$53.96M	-$48.45M
Net Income	-$75.74M	-$64.92M	-$132.06M	-$88.48M	-$86.91M	-$90.86M	-$51.02M	-$161.35M	-$132.74M	-$68.52M	-$48.08M
EPS (Diluted)	n/a	-$0.53	-$1.71	-$1.27	-$1.33	-$1.60	-$1.20	-$3.90	n/a	n/a	n/a
Total Assets	$179.69M	$160.46M	$220.33M	$197.41M	$254.60M	$251.21M	$70.78M	$98.30M	$275.57M	$243.51M	$176.09M
Total Liabilities	$55.11M	$57.38M	$64.77M	$40.23M	$56.98M	$53.87M	$33.13M	$28.39M	$60.44M	$18.25M	$6.59M
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	$10.65M	n/a	$29.91M	n/a	n/a
Shareholders' Equity	$124.58M	$103.08M	$155.55M	$157.18M	$197.62M	$197.34M	$37.65M	$69.91M	$215.12M	$225.26M	$169.49M
Cash & Equivalents	$19.17M	$19.96M	$24.57M	$39.88M	$45.28M	$27.35M	$22.06M	$34.19M	n/a	$20.20M	$30.17M
Operating Cash Flow	-$62.06M	-$47.11M	-$20.07M	-$78.33M	-$67.57M	-$52.13M	-$38.63M	-$96.44M	-$100.81M	-$54.66M	-$34.60M
Capital Expenditures	$118.0K	$111.0K	$121.0K	$1.31M	$605.0K	$308.0K	$453.0K	$1.61M	$1.36M	$1.24M	$232.0K
Free Cash Flow	-$62.18M	-$47.22M	-$20.20M	-$79.63M	-$68.17M	-$52.44M	-$39.09M	-$98.06M	-$102.17M	-$55.90M	-$34.84M
Shares Outstanding	139.82M	120.50M	107.85M	70.89M	66.69M	61.23M	45.11M	41.49M	41.21M	30.86M	26.06M
Weighted Average Diluted Shares	n/a	122.56M	77.30M	69.81M	65.21M	56.73M	42.54M	41.32M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.53	-$1.71	-$1.27	-$1.33	-$1.60	-$1.20	-$3.90	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView